- $1.36bn
- $1.05bn
- $1.29bn
Annual income statement for Progyny, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 501 | 787 | 1,089 | 1,167 | 1,289 |
| Cost of Revenue | |||||
| Gross Profit | 112 | 167 | 239 | 253 | 304 |
| Selling / General / Administrative Expenses | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 468 | 764 | 1,026 | 1,100 | 1,203 |
| Operating Profit | 32.3 | 23.3 | 62.2 | 67.5 | 85.3 |
| Total Net Non Operating Interest Income / Expense | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | 32.4 | 24.4 | 70.7 | 83.2 | 95.4 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 65.8 | 30.4 | 62 | 54.3 | 58.5 |
| Net Income Before Extraordinary Items | |||||
| Net Income | 65.8 | 30.4 | 62 | 54.3 | 58.5 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | 65.8 | 30.4 | 62 | 54.3 | 58.5 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 0.655 | 0.304 | 0.616 | 0.579 | 0.69 |